Intervention not reported
Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Number of participants with any bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in number of participants with any bleeding (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants with clinically significant bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in number of participants with clinically significant bleeding (0 to 3… (low certainty).
1 finding from 1 review
Intervention not reported
Serious infections (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in serious infections (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
Length of hospital admission (days) (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Hospital readmission (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in hospital readmission (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total mortality Duration: 1 to 5.8 years · patients with hypertension
1 finding from 1 review
Cardiovascular events · patients with hypertension
First‐line thiazides probably leads to lower total cardiovascular events Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
First‐line thiazides showed no clear difference in total stroke Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Total CHD Duration: 1 to 5 years · patients with hypertension
First‐line thiazides showed no clear difference in total CHD Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
First‐line thiazides probably leads to lower total congestive heart failure Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Adverse effects (side effects; treatment withdrawals) · patients with hypertension
First‐line thiazides may leads to lower withdrawals due to adverse effects Duration: 1 to 5 years compared with first‐line calcium channel blockers (low certainty).
1 finding from 1 review
Total mortality Duration: 1 to 5 years · patients with hypertension
First‐line thiazides showed no clear difference in total mortality Duration: 1 to 5 years compared with first‐line ACE inhibitors (moderate certainty).
1 finding from 1 review
Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found